Navigation Links
Halting bone-building osteoporosis drug use cuts risk for additional atypical femur fracture in half
Date:2/8/2012

SAN FRANCISCO There is growing evidence that supports an association between atypical fractures of the femur a rare break of the thigh bone, typically without trauma and the use of bisphosphonates, drugs proven to enhance bone density and reduce fracture incidence caused by osteoporosis. While the risk for suffering an atypical femur fracture while taking bisphosphonates is still very small just 1 in 1,000 patients after six years of treatment research presented today at the 2012 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) found that discontinuing bisphosphonate use following an atypical femur fracture can significantly lower the risk for a subsequent atypical fracture.

Scientists believe that bisphosphonates may suppress the body's natural process of remodeling -- where old bone tissue is replaced with new, healthy tissue in some patients, resulting in brittle bones susceptible to atypical fractures, especially in the femur.

Investigators reviewed femur fracture data from Jan. 1, 2007 until Dec. 31, 2009 in patients older than 45 enrolled in a large California HMO. There were 126 patients with an atypical femur fracture who reportedly took bisphosphonates prior to their bone break.

The incidence of a subsequent atypical femur fracture occurring in the other thigh was 53.9 percent in patients who continued bisphosphonates for three or more years after their first fracture, compared to 19.3 percent in patients who discontinued bisphosphonate use. Overall, subsequent atypical femur fractures were decreased by 65.6 percent when bisphosphonates were stopped within one year following the first fracture.

"The risk of a contralateral atypical femur fracture (on the opposite side) increases over time if the bisphosphonates are continued," said lead investigator Richard Dell, MD, a researcher in the Department of Orthopaedics at Kaiser Permanente. "Based on these observations, we recommend discontinuing bisphosphonate use as soon as possible after the initial atypical femur fracture has occurred."

Dr. Dell then recommends the ongoing evaluation of these patients, through X-ray or MRI, as they still are at risk for a subsequent, atypical femur fracture on the other femur.

If the patient is at high risk for other fractures, the study recommends use of an alternative osteoporosis medication.


'/>"/>
Contact: Kristina Goel
goel@aaos.org
847-384-4034
American Academy of Orthopaedic Surgeons
Source:Eurekalert

Related medicine news :

1. Molecular playbook for halting heart failure risk factor uncovered
2. Bone-Building Pills Appear to Lower Invasive Breast Cancer Risk
3. Quantity vs. quality: Long-term use of bone-building osteoporosis drugs
4. Early Ovary Removal May Raise Arthritis, Osteoporosis Risk
5. 1st Middle East and Africa Osteoporosis Meeting opens in Dubai
6. Three steps to unbreakable bones on World Osteoporosis Day
7. Capacity to diagnose osteoporosis doubles in Armenia
8. An important breakthrough at the IRCM associated with osteoporosis
9. Bone experts to present strategies for osteoporosis prevention and care in Dubai
10. Osteoporosis Phase III data at 2011 ASBMR Show oral calcitonin tablet is safe and effective
11. FDA Advisers Call for Revised Labels for Osteoporosis Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) ... Meeting. KLS is a longtime supporter of the event. , "We are pleased ... Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO ... the National Institute for Health and Care Excellence (NICE) framework. The ... National Health Service (NHS) to search, order and purchase medical and healthcare-related content ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global ... announced that Premier Research, a leading clinical development service provider, has selected ERT’s ... increasingly complex, due in part to an array of circumstances including the use ...
(Date:2/23/2017)... VA – , ... ... coming. It’s the perfect opportunity for the nation to come ... a college basketball bracket – with its favorite fruit – ... is encouraging apple lovers to join the “Apple Madness” bracket ...
(Date:2/23/2017)... ... 2017 , ... HealthPostures, the desk for standing designer headquartered in Prior Lake, ... the Minneapolis Home and Garden Show which is being held February 24 through 26 ... is the Minneapolis Convention Center. , From its broad line of sit stand ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Feb 24, 2017 Research and Markets has ... and Strategies - 2016" report to their offering. ... The latest research Urinary ... data and benchmarks in the global Urinary Incontinence market. The ... are the key drugs marketed for Urinary Incontinence and their clinical ...
(Date:2/23/2017)... 2017 LG Innotek hat heute die weltweit ... beträgt das 1,5-fache des 45-mW-Moduls der Konkurrenz. ... 200 und 280 nm und eignet sich damit für Sterilisationsaufgaben. ... DNA zerstört. Das Produkt von LG Innotek erzeugt UV-Strahlung ... ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Menopause ... ... Drugs Price Analysis and Strategies - 2016, provides drug pricing data and ... questions: What are the key drugs marketed ... Global Menopause market? What are the unit prices and ...
Breaking Medicine Technology: